Company / Working Capital
Neurocrine Biosciences Working Capital History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Working Capital
$1.8B
FY2025
5-year range
$727.0M / $1.8B
FY2021-FY2025
Trend
+46.2%
vs FY2024
Sector context
#27 of 215
Health Care
What the data says
Neurocrine Biosciences's working capital of $1.8B is higher than 87% of companies in the Health Care sector (FY2025). Working Capital has increased for 4 consecutive years, from $727M in FY2021 to $1.8B in FY2025.
Based on SEC 10-K filings.
$1.8B in FY2025 with a 5-year CAGR of +16.5%. Top quartile in the Health Care sector.
Improved from $952M to $1.8B over the past 2 years.
Health Care sector context is included.
Working Capital over time
Growth rates
- 3-Year CAGR
- +24.8%
- 5-Year CAGR
- +16.5%
- 10-Year CAGR
- -
Sector benchmark
Top 13% in Health CareTop 13% of 215This company $1.8B Sector average $957.8M
▼
+85.8% above sector average
Key checks
Key Insights
- Neurocrine Biosciences's working capital has grown for 4 consecutive years.
- 5-year CAGR of +16.5%, indicating consistent growth.
- In FY2025, working capital increased 46.2% year-over-year.
- Ranks #27 out of 215 companies in the Health Care sector.
Company context
Key Data Points
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Working CapitalValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $1.8B | +46.2% |
| FY2024 | $1.2B | +27.8% |
| FY2023 | $952.2M | +4.0% |
| FY2022 | $915.8M | +26.0% |
| FY2021 | $727.0M | -12.4% |
| FY2020 | $829.7M | +212.3% |
| FY2019 | $265.7M | -59.1% |
| FY2018 | $649.5M | +29.8% |
| FY2017 | $500.5M | +78.7% |
| FY2016 | $280.0M | -21.9% |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026